Treatment with B-cell directed therapies, such as anti-CD20 monoclonal antibodies and Bruton’s tyrosine kinase (BTK) inhibitors, further compromises the ability of patients with lymphoma to mount an antibody response following vaccination and persists over time [8]. This evidence concerns the gene BTK and lymphoma.